The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Abstract
An increasingly competitive pharmaceutical market demands improvement in the efficiency and probability of drug candidate discovery. Usually these new drug candidates are targeted for oral administration, so a detailed understanding of the molecular-level properties that relate to optimal pharmacokinetics is a critical step toward improving the probability of selecting successful clinical candidates. Although the characteristics of druglike molecules have been previously discussed in the literature, the importance of this topic sustains a continued interest for additional perspective and further detailed statistical analyses. In this contribution, we approach the analysis from the perspective of profiling distinguishing features of orally administered drugs. We have compiled both structural and route-administration information for a total of 1729 marketed drugs to provide a solid basis for developing a new perspective on the characteristics of over 1000 orally administered drugs. The molecular properties and most commonly occurring structural elements are statistically analyzed to capture the differences between routes of administration, as well as between marketed drugs and SAR or clinical compounds. We find that, with respect to other routes of administration, oral drugs tend to be lighter and have fewer H-bond donors, acceptors, and rotatable bonds than drugs with other routes of administration. These differences are particularly pronounced when comparing the mean values for oral vs injectable drugs. We also demonstrate that the mean property values for oral drugs do not vary substantially with respect to launch date, suggesting that the range of acceptable oral properties is independent of synthetic complexity or targeted receptor. Finally, we note that, while these properties are descriptive of each class, they are not necessarily predictive of what class any particular drug will reside in, since there is significant overlap in the acceptable ranges found for each drug class.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Cited by
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Medicinal chemical properties of successful central nervous system drugs
Pajouhesh, H., & Lenz, G. R. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.541 · Cited by 1,535
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
970 Million Druglike Small Molecules for Virtual Screening in the Chemical Universe Database GDB-13
Blum, L. C., & Reymond, J.-L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902302h · Cited by 860
Rees, D. C., Congreve, Murray, C. W., & Carr, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1467 · Cited by 798
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Recent Developments in Fragment-Based Drug Discovery
Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 611
Experimental Binding Energies in Supramolecular Complexes
Biedermann, F., & Schneider, H.-J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00583 · Cited by 554
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
Macrocycles In New Drug Discovery
Mallinson, J., & Collins, I. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.93 · Cited by 468
Comparison of descriptor spaces for chemical compound retrieval and classification
Wale, N., Watson, I. A., & Karypis, G. (2008) · Knowledge and Information Systems · doi:10.1007/s10115-007-0103-5 · Cited by 453
Self-citationShultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Villar, E. A., Beglov, D., Chennamadhavuni, S., Porco, J. A., Kozakov, D., Vajda, S., & Whitty, A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1584 · Cited by 400
MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories
Schmidtke, P., Bidon-Chanal, A., Luque, F. J., & Barril, X. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr550 · Cited by 395
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Classification of scaffold-hopping approaches
Sun, H., Tawa, G., & Wallqvist, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.024 · Cited by 375
In vitro models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Abrahamsson, B., Brewster, M., Brouwers, J., Butler, J., Carlert, S., Dickinson, P. A., Dressman, J., Holm, R., Klein, S., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.024 · Cited by 373
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
The significance of acid/base properties in drug discovery
Manallack, D. T., Prankerd, R. J., Yuriev, E., Oprea, T. I., & Chalmers, D. K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35348b · Cited by 329
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Targeting protein kinases in central nervous system disorders
Chico, L. K., Van Eldik, L. J., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 298
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs
Whitty, A., Zhong, M., Viarengo, L., Beglov, D., Hall, D. R., & Vajda, S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.005 · Cited by 285
Ligand efficiency indices for effective drug discovery
Abad-Zapatero, C. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.469 · Cited by 279
Booth, B., & Zemmel, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1384 · Cited by 278
Assessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Fragment-Based Lead Discovery and Design
Joseph-McCarthy, D., Campbell, A. J., Kern, G., & Moustakas, D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400731w · Cited by 129
Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds
BRUSEWITZ, C., SCHENDLER, A., FUNKE, A., WAGNER, T., & LIPP, R. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.08.022 · Cited by 86
Oftedal, L., Selheim, F., Wahlsten, M., Sivonen, K., Døskeland, S. O., & Herfindal, L. (2010) · Marine Drugs · doi:10.3390/md8102659 · Cited by 62
Metadata
- Authors
- Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2003-11-26
- Volume
- 47
- Issue
- 1
- Pages
- 224-232
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1999711931
- Cited by
- 359
- References
- 1
- FWCI
- 24.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.